159 related articles for article (PubMed ID: 34885201)
1. Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas.
Yu G; Pang Y; Merchant M; Kesserwan C; Gangalapudi V; Abdelmaksoud A; Ranjan A; Kim O; Wei JS; Chou HC; Wen X; Sindiri S; Song YK; Xi L; Kaplan RN; Armstrong TS; Gilbert MR; Aldape K; Khan J; Wu J
Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885201
[TBL] [Abstract][Full Text] [Related]
2. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
[TBL] [Abstract][Full Text] [Related]
3. Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma.
Nejo T; Matsushita H; Karasaki T; Nomura M; Saito K; Tanaka S; Takayanagi S; Hana T; Takahashi S; Kitagawa Y; Koike T; Kobayashi Y; Nagae G; Yamamoto S; Ueda H; Tatsuno K; Narita Y; Nagane M; Ueki K; Nishikawa R; Aburatani H; Mukasa A; Saito N; Kakimi K
Cancer Immunol Res; 2019 Jul; 7(7):1148-1161. PubMed ID: 31088845
[TBL] [Abstract][Full Text] [Related]
4. [Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. German version].
Malzkorn B; Reifenberger G
Pathologe; 2019 Mar; 40(2):131-139. PubMed ID: 30790013
[TBL] [Abstract][Full Text] [Related]
5. Application of Distributed Parameter Model to Assessment of Glioma IDH Mutation Status by Dynamic Contrast-Enhanced Magnetic Resonance Imaging.
Li Z; Zhao W; He B; Koh TS; Li Y; Zeng Y; Zhang Z; Zhang J; Hou Z
Contrast Media Mol Imaging; 2020; 2020():8843084. PubMed ID: 33299387
[TBL] [Abstract][Full Text] [Related]
6. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
Malzkorn B; Reifenberger G
Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
[TBL] [Abstract][Full Text] [Related]
7. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
8. Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic
Vettermann F; Suchorska B; Unterrainer M; Nelwan D; Forbrig R; Ruf V; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2581-2589. PubMed ID: 31410540
[TBL] [Abstract][Full Text] [Related]
9. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis.
Suwala AK; Stichel D; Schrimpf D; Kloor M; Wefers AK; Reinhardt A; Maas SLN; Kratz CP; Schweizer L; Hasselblatt M; Snuderl M; Abedalthagafi MSJ; Abdullaev Z; Monoranu CM; Bergmann M; Pekrun A; Freyschlag C; Aronica E; Kramm CM; Hinz F; Sievers P; Korshunov A; Kool M; Pfister SM; Sturm D; Jones DTW; Wick W; Unterberg A; Hartmann C; Dodgshun A; Tabori U; Wesseling P; Sahm F; von Deimling A; Reuss DE
Acta Neuropathol; 2021 Jan; 141(1):85-100. PubMed ID: 33216206
[TBL] [Abstract][Full Text] [Related]
10. Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma.
Richardson TE; Yokoda RT; Rashidipour O; Vij M; Snuderl M; Brem S; Hatanpaa KJ; McBrayer SK; Abdullah KG; Umphlett M; Walker JM; Tsankova NM
Neurooncol Adv; 2023; 5(1):vdad085. PubMed ID: 37554222
[TBL] [Abstract][Full Text] [Related]
11. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
12. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
[TBL] [Abstract][Full Text] [Related]
13. Biological tumour volumes of gliomas in early and standard 20-40 min
Unterrainer M; Winkelmann I; Suchorska B; Giese A; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1242-1249. PubMed ID: 29487977
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional Characteristics of
Chang YZ; Li GZ; Pang B; Zhang KN; Zhang XH; Wang YZ; Jiang ZL; Chai RC
Front Cell Dev Biol; 2020; 8():580464. PubMed ID: 33195221
[No Abstract] [Full Text] [Related]
15. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
16. Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI.
Jiang S; Zou T; Eberhart CG; Villalobos MAV; Heo HY; Zhang Y; Wang Y; Wang X; Yu H; Du Y; van Zijl PCM; Wen Z; Zhou J
Magn Reson Med; 2017 Sep; 78(3):1100-1109. PubMed ID: 28714279
[TBL] [Abstract][Full Text] [Related]
17. Germline ALK variations are associated with a poor prognosis in glioma and IDH-wildtype glioblastoma.
Bu L; Hameed NUF; Luo C; Hong P; Zhou X; Wang S; Wu S
J Neurooncol; 2021 Mar; 152(1):27-36. PubMed ID: 33486679
[TBL] [Abstract][Full Text] [Related]
18. IDH mutation, glioma immunogenicity, and therapeutic challenge of primary mismatch repair deficient IDH-mutant astrocytoma PMMRDIA: a systematic review.
Ahmad O; Ahmad T; Pfister SM
Mol Oncol; 2024 Feb; ():. PubMed ID: 38339779
[TBL] [Abstract][Full Text] [Related]
19. Identification of IDH and TERTp mutation status using
Ozturk-Isik E; Cengiz S; Ozcan A; Yakicier C; Ersen Danyeli A; Pamir MN; Özduman K; Dincer A
J Magn Reson Imaging; 2020 Jun; 51(6):1799-1809. PubMed ID: 31664773
[TBL] [Abstract][Full Text] [Related]
20. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.
Bale TA; Jordan JT; Rapalino O; Ramamurthy N; Jessop N; DeWitt JC; Nardi V; Alvarez MM; Frosch M; Batchelor TT; Louis DN; Iafrate AJ; Cahill DP; Lennerz JK
Neuro Oncol; 2019 May; 21(5):596-605. PubMed ID: 30496526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
